LEADER 03966nam 22006614a 450 001 9910876807403321 005 20200520144314.0 010 $a1-280-27526-X 010 $a9786610275267 010 $a0-470-02142-X 010 $a0-470-02141-1 035 $a(CKB)1000000000357241 035 $a(EBL)232685 035 $a(SSID)ssj0000170472 035 $a(PQKBManifestationID)11171219 035 $a(PQKBTitleCode)TC0000170472 035 $a(PQKBWorkID)10223946 035 $a(PQKB)10515328 035 $a(MiAaPQ)EBC232685 035 $a(OCoLC)85820613 035 $a(EXLCZ)991000000000357241 100 $a20041130d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe hERG cardial potassium channel $estructure, function, and long QT syndrome /$f[editors, Derek J. Chadwick, James Goode] 210 $aNew York $cJ. Wiley$d2005 215 $a1 online resource (309 p.) 225 1 $aNovartis Foundation symposium ;$v266 300 $aBased on a symposium. 311 $a0-470-02140-3 320 $aIncludes bibliographical references and indexes. 327 $aTHE hERG CARDIAC POTASSIUM CHANNEL: STRUCTURE, FUNCTION AND LONG QT SYNDROME; Contents; Participants; Chair's introduction; Gating and assembly of heteromeric hERG1a/1b channels underlying I(Kr) in the heart; Discussion; Structure-function studies of the outer mouth and voltage sensor domain of hERG; Discussion; General discussion I; Voltage sensor movement in the hERGK(+) channel; Discussion; hERG channel trafficking; Discussion; Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3; Discussion; General discussion II 327 $aDoes hERG coassemble with a b subunit? Evidence for roles of MinK and MiRP1Discussion; hERG block, QT liability and sudden cardiac death; Discussion; Structural determinants for high-affinity block of hERG potassium channels; Discussion; Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs; Discussion; In silico modelling-pharmacophores and hERG channel models; Discussion; The long QTsyndrome: a clinical counterpart of HERG mutations; Discussion; Cellular mechanisms of Torsade de Pointes; Discussion 327 $aExpression and role of hERG channels in cancer cellsDiscussion; TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability); Discussion; Drug-induced QT interval prolongation: regulatory guidance and perspectives on hERG channel studies; Discussion; Closing remarks; Index of contributors; Subject index 330 $aThis book draws together contributions from basic, pharmaceutical and clinical sciences aimed at a better understanding of the structure and function of hERG and the molecular basis for compound binding. It features regulatory authority perspectives on preferred preclinical test systems and includes topics on hERG channel gating, regulation of functional expression, pharmacological properties of hERG/IKr channels, drug-induced long QT syndrome and preclinical evaluation and regulatory recommendations for assessing QT prolongation risks. Better understanding of the role of the hERG channe 410 0$aNovartis Foundation symposium ;$v266. 606 $aPotassium channels$vCongresses 606 $aLong QT syndrome$vCongresses 606 $aHeart$xPhysiology$vCongresses 606 $aHeart$xPathophysiology$vCongresses 615 0$aPotassium channels 615 0$aLong QT syndrome 615 0$aHeart$xPhysiology 615 0$aHeart$xPathophysiology 676 $a612.1/7 701 $aChadwick$b Derek$091632 701 $aGoode$b Jamie$0283336 712 02$aNovartis Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910876807403321 996 $aThe hERG cardial potassium channel$94204539 997 $aUNINA